| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/18/2005 | CN1615896A Medicine for regulating blood fat and treating cardiocerehral disease and preparing method |
| 05/18/2005 | CN1615894A Notoginseng total saponin amino acid transfusion liquid and its producing method |
| 05/18/2005 | CN1615873A Azaindoles compound |
| 05/18/2005 | CN1615862A Miglitol oral disintegration tablet for treating diabetes II and its preparing method |
| 05/18/2005 | CN1615851A Process for preparing gliclazide slow release capsule for oral sugar reducing method |
| 05/18/2005 | CN1615850A Gliclazide slow release capsule for oral sugar reducing medicine |
| 05/18/2005 | CN1615847A Use of scopoletin in preparing medicine for preventing and curing hyperuricemia |
| 05/18/2005 | CN1615839A Utilization of dialkylfumarates |
| 05/18/2005 | CN1615830A Amfepramone hydro chloride dripping pill |
| 05/18/2005 | CN1615828A Garlicin injection emulsion and its preparing method |
| 05/18/2005 | CN1615822A Fat milk transfusion fluid for treating pulmonary heart disease and energy supplement and its producing method |
| 05/18/2005 | CN1202257C Recombination carrier and treating composition used in insulin dependent diabetes gene curing |
| 05/18/2005 | CN1202118C Adenosine derivatives |
| 05/18/2005 | CN1202103C Preparation method of red sageroot total phenolic acid |
| 05/18/2005 | CN1202096C 2-aminothiazoline derivatives and their use as no-synthase inhibitors |
| 05/18/2005 | CN1202067C Method for preparing medicinal grade ferric citrate |
| 05/18/2005 | CN1201790C Chinese medicine powder for treating diabetes II |
| 05/18/2005 | CN1201783C Oral liquid for replenishing vital essence, removing dryness and reducing glucose |
| 05/18/2005 | CN1201776C Medicinal composition for treating diabetes and its prepn |
| 05/18/2005 | CN1201774C Medicine for treat hyperlipemia |
| 05/18/2005 | CN1201769C Medicine for treating diabetes, nephropathy |
| 05/18/2005 | CN1201768C Medication for treating diabetic retinopathy and its preparing method |
| 05/18/2005 | CN1201743C Composition of gensenoside Rg1 and ferulic acid for preventing and treating cardiac and cerebral vascular diseases and diabetes and its application |
| 05/18/2005 | CN1201742C Hypoglycemic health-care food for diabetes type II |
| 05/18/2005 | CN1201733C Omega-3 fatty acid capsule |
| 05/18/2005 | CN1201731C Medicine preparation and its use and the use of high grade primary alcohol mixture |
| 05/17/2005 | US6894155 Immumodulatory protein for use in the treatment of nervous system, skin and immunological disorders |
| 05/17/2005 | US6894067 5-heteroatom-substituted pyrazoles |
| 05/17/2005 | US6894065 For therapy of thrombosis, platelet aggregation, coagulation, cancer, inflammatory diseases or respiratory diseases |
| 05/17/2005 | US6894058 Administering statin drug |
| 05/17/2005 | US6894050 3,4,5,6-tetrahydro-2h-(1,2')bipyrazinyl derivatives |
| 05/17/2005 | US6894047 Triazine compounds useful as sorbitol dehydrogenase inhibitors |
| 05/17/2005 | US6894042 Azabicyclic compounds for the treatment of disease |
| 05/17/2005 | US6894041 Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes |
| 05/17/2005 | US6894038 Administering an estriol 3,17-dipropionate or an estriol 3,17-dihexanoate, for treating multiple sclerosis |
| 05/17/2005 | US6894036 4-dedimethylaminotetracycline derivatives |
| 05/17/2005 | US6893838 DADD, death activator death domain protein |
| 05/17/2005 | US6893833 Use of NAD(P)H oxidase inhibitors to increase cellular uptake of glucose and in the treatment and/or prevention of diseases caused by insulin resistance or diseases related thereto, such as type II diabetes |
| 05/17/2005 | US6893641 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 05/17/2005 | US6893627 Method for treating type 2 diabetes with an extract of Artemisia |
| 05/17/2005 | CA2335492C Pyrrolo[2,3-d]pyrimidine compounds |
| 05/17/2005 | CA2057099C Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals |
| 05/12/2005 | WO2005042727A2 Methods of organ regeneration |
| 05/12/2005 | WO2005042692A2 A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
| 05/12/2005 | WO2005042483A1 [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-((1-methylethyl) -3-phenyl-4-[(phenylamino) carbonyl]- 1h-pyrrole-1-heptanoic acid iron salt |
| 05/12/2005 | WO2005041995A1 α-GLUCOSIDASE ACTIVITY INHIBITOR |
| 05/12/2005 | WO2005016514A3 Combinatorial synthesis on support |
| 05/12/2005 | WO2003070903A3 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/12/2005 | WO2002072591A8 Resveratrol-phospholipids complexes |
| 05/12/2005 | US20050101798 C2-substituted idan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals |
| 05/12/2005 | US20050101779 Antagonistic activity to alpha 4 integrin; antiinflammatory agents treating asthma, rheumatoid arthritis, inflammatory bowel diseases, lupus, diabetes; 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl(2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[1-methyl-2,4-dioxo-1,4-tetrahydro-3-(2H)quinazolinyl]phenyl]Propionate |
| 05/12/2005 | US20050101775 Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging |
| 05/12/2005 | US20050101664 Anionically coupling an acyl imidazoyl carbamate with a primary amide or carbamate; N-alkylation; inosine-5*-monophosphate dehydrogenase inhibitors |
| 05/12/2005 | US20050101658 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| 05/12/2005 | US20050101649 nicotinic alpha 7 receptor and 5-HT3 or 5-HT6 receptor; control of cholinergic and dopaminergic neurotransmission; disorders of the central nervous system and serotonergic hyperactivity; psychiatric and neurodegenerativce disorders; antiemetics during chemotherapy |
| 05/12/2005 | US20050101637 Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals |
| 05/12/2005 | US20050101636 PPAR-activating compound and pharmaceutical composition comprising the compound |
| 05/12/2005 | US20050101615 Pyridopyrimidine or naphthyridine derivative |
| 05/12/2005 | US20050101612 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases |
| 05/12/2005 | US20050101611 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor |
| 05/12/2005 | US20050101610 Antiischemic agents; brain disorders; cardiovascular disorders; for the alleviation or treatment of symptoms due to neurodegenerative diseases and symptoms derived from diabetes, arteriosclerosis and inflammatory diseases ; for example, N-tert-butoxycarbonyl-4-[4-(4-fluorophenoxy)phenyl]-4-piperidinol |
| 05/12/2005 | US20050101585 Cannabis-1 (CB1) receptor antagonists; for treatment/inhibiton of drug induced obesity in juveniles/adolescents |
| 05/12/2005 | US20050101578 2-Alkylidene-19-nor-vitamin D derivatives for the treatment of hypocalcemic tetany or hypoparathyroidism |
| 05/12/2005 | US20050101577 2-alkylidene-19-nor-vitamin D derivatives for the treatment of rickets or vitamin D deficiency |
| 05/12/2005 | US20050101575 Vitamin d3 derivatives and remedies using the same |
| 05/12/2005 | US20050101567 Using a sulfonamide containing compound |
| 05/12/2005 | US20050101565 Using mixture containing pantethine |
| 05/12/2005 | US20050101563 Using cyclooxygenase inhbitor and fatty acid; analgesics; antiinflammatory agents; antiarthritic agents; vision defects; urogenital disorders; gastrointestinal disorders |
| 05/12/2005 | US20050101562 Lipase inhibiting composition |
| 05/12/2005 | US20050101546 Increased solubility flavanolignan preparations |
| 05/12/2005 | US20050101537 Use of exendins and agonists thereof for lowering plasma lipid |
| 05/12/2005 | US20050101532 Protamine fragment compositions and methods of use |
| 05/12/2005 | US20050101529 Protein modification and maintenance molecules |
| 05/12/2005 | US20050101521 Bind as ligands to human peroxisome proliferator activated receptor to activate receptor and thereby exhibit potent effects of decreasing neutral fat, cholesterol, and blood sugar; for example, 2-[[4-ethoxy-3-[[[4-(2-pyridyloxy)phenyl]carbonylamino]methyl]phenyl]methyl]butyric acid; diabetes treatment |
| 05/12/2005 | US20050100918 Mammalian receptor proteins; related reagents and methods |
| 05/12/2005 | US20050100917 Mammalian receptor proteins; related reagents and methods |
| 05/12/2005 | US20050100894 Novel mitogen activated kinase |
| 05/12/2005 | US20050100617 Method for improving age-related physiological deficits and increasing longevity |
| 05/12/2005 | US20050100615 controling metabolic acidosis due to burn injury, hemorrhagic shock, multiple organ failure, systemic inflammatory response syndrome (SIRS); administering sodium bicarbonate |
| 05/12/2005 | US20050100614 Chromium bound to niacin and three compounds from the group consisting of (-) hydroxycitric acid, zinc (particularly zinc methionine), trans-reseveratrol, gymnernic acid, selenium, an anthocyanidin, allicin, and fenugreek. |
| 05/12/2005 | US20050100541 Ligands, including antibodies, showing reactivity against endocrine cells |
| 05/12/2005 | CA2544781A1 Plant-derived .beta.3-adrenergic receptor agonist substances and uses thereof |
| 05/12/2005 | CA2544425A1 Alpha-glucosidase activity inhibitor |
| 05/12/2005 | CA2544317A1 Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists |
| 05/12/2005 | CA2544310A1 New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof |
| 05/12/2005 | CA2543745A1 Methods of organ regeneration |
| 05/12/2005 | CA2543716A1 Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| 05/12/2005 | CA2543533A1 2-cyanopyrrolidinecarboxamide compound |
| 05/12/2005 | CA2543528A1 Placental stem cells and uses thereof |
| 05/12/2005 | CA2543238A1 Compositions and dosage forms for enhanced absorption |
| 05/12/2005 | CA2543227A1 Administration of levodopa and carbidopa |
| 05/12/2005 | CA2543181A1 Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin |
| 05/12/2005 | CA2543177A1 Compositions and dosage forms for enhanced absorption of metformin |
| 05/12/2005 | CA2543122A1 3-(4-aminophenyl) thienopyrimid-4-one derivatives as mch r1 antagonists for the treatment of obesity, diabetes, depression and anxiety |
| 05/12/2005 | CA2539446A1 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| 05/11/2005 | EP1529534A2 Use of GLP-1 peptides |
| 05/11/2005 | EP1529530A1 Compounds affecting glucokinase |
| 05/11/2005 | EP1529529A1 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for immunomodulation, immunostimulation and/or antiphlogistic treatment |
| 05/11/2005 | EP1529528A1 2-pyrrolidone derivatives and their use in protecting mammalian cells against oxidation stress |
| 05/11/2005 | EP1529108A2 Albumin-fused ciliary neurotrophic factor |